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November 20121294 Brewster et alrotid artery occlusion is not proven,10 and yet our group
recommends therapy in these patients when their stenosis is
80%, we have initiated a collaboration with our neurology
colleagues to examine the stroke/death rate of patients
with contralateral occlusion who are treated medically or
with an intervention. Further, aggressive blood pressure
management and proper medical therapy is essential to
the care of these patients as demonstrated recently by the
surprisingly good results of medical therapy in both the
CarotidOcclusion Surgery Study17 and Stenting vs Aggres-
sive Medical Management for Preventing Recurrent Stroke
in Intracranial Stenosis18 trials. Improving the initiation
and compliance of optimal medical therapy, including sta-
tin, antiplatelets, and proper antihypertensive medications,
will likely be critical to not only limiting procedural mor-
bidity andmortality but also in maximizing survival of these
patients after successful carotid artery therapy.
CONCLUSIONS
CAS was not associated with improved outcomes com-
pared to CEA in patients with contralateral occlusion. We
do not think that contralateral occlusion is a clinically
important reason for choosing CAS over CEA, but the
majority of patients (30 of 39) undergoing CAS with
contralateral occlusion had other reasons for choosing
CAS, which limits the impact of these findings. The role of
carotid artery therapy in asymptomatic patients with con-
tralateral occlusion remains undefined in the current era.
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Dr Charles B. Ross (Louisville, Ky). This report from the
Emory University group, excellently presented by Dr Brewster,
seeks to answer whether or not contralateral carotid occlusion
(CCO) is an important reason to prefer CAS over CEA in patients
requiring invasive carotid intervention. I appreciated receipt of the
manuscript well before the meeting.
In this study, 39 patients were treated by CAS, and more than
one half of these had “hostile necks.” There were 18 cases treated
by CEA, and almost all of these operations were performed withomatic status or traditional risk factors. No perioperative strokes
r MIs were observed in either group, but two TIAs were noted
fter CAS. One death from retroperitoneal hematoma occurred
fter CAS, and one death occurred shortly after discharge due to a
eizure, apparently not related to hyperperfusion.
Based on the data, it is concluded that CCO is not an impor-
ant reason to choose CAS over CEA. I have a few questions and a
omment.
Six deaths were observed in the CAS group over a follow-up of
nly 28  15 months. In my own practice, I have encountered
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Volume 56, Number 5 Brewster et al 1295referrals for CAS in patients who have limited prognoses. I have
said “no” to CAS and managed these patients medically. In retro-
spect, would medical management have been more appropriate for
some of the patients treated in your CAS group?
What was the timing and presumed cause of the TIAs in the
CAS group? Were there technical or other management issues? We
treat all patients who undergo CAS with dual antiplatelet therapy,
but one problem we have recently encountered has been resistance
to clopidogrel. We now routinely check platelet function assays
before taking our patients to the laboratory for CAS.
Given that the presence of a “hostile neck” is considered by
many to be one of the more solid reasons to perform CAS as
opposed to CEA, would you manage these patients differently
now? More importantly, which patients/indications does your
group feel are appropriate candidates for CAS? What is the Emory
practice now?
Finally, I have concerns that your numbers are too small to
support the conclusion made by this article. This report, like many
other individual reports from busy carotid practices and meta-
analyses of the same, shows excellent surgical results in patients
with CCO. Yet, two important publications within the past year
detailing large numbers of patients, one from the Vascunet Euro-
pean Group and the other from the New England Vascular Study
Group, have shown that CCO increases the risk of perioperative
stroke/death after CEA by a factor of approximately two. This has
not been true for CAS. So, proponents of CAS for carotid inter-
vention in the setting of CCO still have a strong argument.
I thank the Society for the opportunity to initiate this discus-
sion.
Dr Luke P. Brewster. Thank you, Dr Ross. Thank you also for
meeting with me to discuss the article. I agree completely that the
stratification of patients with regard to lifespan is critical to the proper
application of carotid artery therapy. I do not think anything has
changed since NASCET or ACAS to suggest benefits in persons not
expected to live 2 or 5 years. In our series, one of the late deaths had
a home oxygen requirement before therapy. Chronic obstructive
pulmonary disease is another predictor of decreased lifespan, but I do
not think that the diagnosis of chronic obstructive pulmonary disease
is elegant enough to stratify patients. Pulmonary function tests, forced
expiratory volume in 1 second or diffusion capacity for carbon mon-
oxide in particular, may be helpful, particularly in asymptomatic
patients. Regardless, I think expected lifespan after the procedure and
expected outcome of the procedure need to be examined together. If
I remember correctly, Dr Goodney’s group looked at the application
of carotid therapy in the Medicare population and found many
surgeries were performed in persons that were unlikely to live long
enough to benefit. The TIAs were both during the procedure and
m
tere self-limited that one occurred during the ballooning and one
ccurred after retrieving the sheath into the aorta. Presumably, I
ould think that these would be embolic in nature. We do not check
latelet resistance, but I like your approach. Certainly adequate acti-
ated clotting time levels are critical to carotid stenting. Platelet
esistance is a real problem but the most recent meta-analysis looking
t Plavix in the context of specific mutations found a null effect. Our
ndications forCAS are both anatomic andmedical. I think the caveats
re persons with valvular disease. We have had a couple of these
atients decompensate after bradycardia or hypotension; they do not
ave the capacity to tolerate this complication. Now I would add that
ontralateral occlusion is not an indication for carotid stenting.
I would not handle patients that have contralateral occlusion
nd other indications for carotid stenting differently because we
id not find carotid stenting harmful in this population; rather it
rovided no benefit over endarterectomy. Dr Ross, you brought
p two recent articles – one I knew well and one I learned from
ou. The former was from the New England Study Group, and the
atter looked at results out of Europe’s Vascunet Group. Vascunet
ad about 75% symptomatic patients and they studied people up
ntil, I think, 2009 and similarly with the New England Study
roup; both groups looked exclusively at endarterectomy. The
ew England Study Group did look at the benefit of shunt by
eople who routinely placed them vs those that did not. I think
hat the major finding here was that surgeons who shunt routinely
o better shunting patients with contralateral occlusion. We fully
upport shunting these patients. Vascunet found higher stroke
ates in patients with contralateral occlusion. Our study is not
owered to refute theirs (1700 patients). With regards to the
idterm mortality we identified, Dr Eskadari, who is here along
ith one of my colleagues from General Surgery training, Mark
eldahl, recently published Northwestern’s experience looking at
AS in patients with contralateral occlusion. They found a 25%
ortality rate at a mean follow-up of 4 years. Our rate here is
imilar. Being that the peak age for carotid therapy is about 70
ears, and the average age people are now living is to the mid 80s,
think long-term restenosis is going to be a critical parameter to
ollow. I completely support Dr Ross’ recent article calling upon
etter documentation and reporting of carotid stents over time.
his is a long-term goal of Emory’s database, trying to find out
ow patients do after carotid therapy over time. In fact, what first
ot me interested in this question was the article from Bill Baker at
oyola that showed there was questionable benefit of CEA in
atients with contralateral occlusion in the ACAS trial. In sum-
ary, future reporting of outcomes will be well served, including
idterm or later outcomes, and I think we will be able as a Society
o address with Vascular Quality Initiative.
